CERO

CERO

USD

CERo Therapeutics Holdings Inc. Common Stock

$0.095-0.240 (-71.620%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
संयुक्त राज्य अमेरिका

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$0.335

उच्च

$0.095

कम

$0.095

मात्रा

8.44M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

177.4K

उद्योग

जैव प्रौद्योगिकी

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

2.29M

एक्सचेंज

NCM

मुद्रा

USD

52-सप्ताह रेंज

कम $0.062वर्तमान $0.095उच्च $896

संबंधित समाचार

Analyst Upgrades

Maxim Group Downgrades CERo Therapeutics Hldgs to Hold

Maxim Group analyst Jason McCarthy downgrades CERo Therapeutics Hldgs from Buy to Hold.

और देखें
Maxim Group Downgrades CERo Therapeutics Hldgs to Hold
Analyst Upgrades

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs with a Buy and maintains $30 price target.

और देखें
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
GlobeNewswire

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Markets and continue

और देखें
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
Analyst Upgrades

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs with a Buy and maintains $30 price target.

और देखें
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
GlobeNewswire

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.

और देखें
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
GlobeNewswire

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company, announces that Chris Ehrlich,

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।